Cargando…
CSACI position statement: prescribing sublingual immunotherapy tablets for aeroallergens
Autores principales: | Quirt, J., Gagnon, R., Ellis, A. K., Kim, H. L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5759887/ https://www.ncbi.nlm.nih.gov/pubmed/29339956 http://dx.doi.org/10.1186/s13223-017-0225-6 |
Ejemplares similares
-
Use of Sublingual Immunotherapy for Aeroallergens in Children with Asthma
por: Caffarelli, Carlo, et al.
Publicado: (2020) -
CSACI position statement: safety of topical calcineurin inhibitors in the management of atopic dermatitis in children and adults
por: Segal, Audrey O, et al.
Publicado: (2013) -
CSACI Position statement on the testing of food-specific IgG
por: Carr, Stuart, et al.
Publicado: (2012) -
CSACI position statement: epinephrine auto-injectors and children < 15 kg
por: Halbrich, Michelle, et al.
Publicado: (2015) -
CSACI position statement: transition recommendations on existing epinephrine autoinjectors
por: Li, Lucy Dong Xuan, et al.
Publicado: (2021)